StockData

Shoulder Innovations vs TELA Bio

SI and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SI and TELA compare

Shoulder Innovations is the larger company, worth 12 times as much as TELA Bio ($431M against $36.8M).

Shoulder Innovations grew revenue faster over the last twelve months (54.9% versus 1.5% for TELA Bio).

Shoulder Innovations keeps more of each dollar of sales as profit, with a net margin of −51.7% compared with −53.6% at TELA Bio.

Shoulder Innovations scores higher on the StockData Score (8 against 3 for TELA Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSITELA
Size and price
Market cap$431M$36.8M
Share price$20.69$0.820
Change, 1 year37.9%−28.1%
Change, 5 years–−93.5%
Beta (5Y)–0.62
Employees75218
StockData Score
Total score8 (better)3
Valuation score01 (better)
Growth score3 (better)1
Performance score11
Health score4 (better)0
Dividend score00
Valuation
P/S6.7×0.5× (better)
P/B3.6×–
FCF yield−9.9% (better)−93.4%
Fair value$13.60–
Margin of safety−52.1%–
Growth
Revenue growth (TTM)54.9% (better)1.5%
Revenue growth, 5Y average–34.5%
Profitability
Gross margin77.8% (better)67.2%
Operating margin−54.4%−43.2% (better)
Net margin−51.7% (better)−53.6%
FCF margin−66.2%−44.0% (better)
Return on equity−25.1%–
Return on invested capital−83.6% (better)−238%
Financial health
Debt / equity0.13–
Interest coverage–−4.3×
Current ratio10.68 (better)0.61
Altman Z-score8.96 (better)−13.23
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.8%70.5%
Held by insiders40.0%41.0%
Insider net buying, 12 months−$5.3M$186K (better)
Short interest, % of float5.7%2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.